Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection

  • Atrasheuskaya A
  • Petzelbauer P
  • Fredeking T
  • et al.
N/ACitations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Here we describe a lethal mouse model infected with dengue virus type 2 with several similarities to human DEN-2 infection. Clinically animals demonstrated anemia, thrombocytopenia, pre-terminal paralysis and shock. The most impressive changes were seen with tumor necrosis factor (TNF)-K, which abruptly and steeply increased 24 h before the exitus (mean at day 6). Serum levels of IL-1L, IL-6, IL-10, IL-1 receptor antagonist and soluble TNF receptor I continuously increased during the time of infection. A 100% mortality rate was noted in that group of animals. Treating animals with anti-TNF-K serum reduced mortality rate down to 40% (P 6 0.05). Our model supports the view that activation of innate immune response is at least partially responsible for mortality in DEN-2 infection, and in line with this concept, anti-TNF treatment significantly reduces mortality rates.

Cite

CITATION STYLE

APA

Atrasheuskaya, A., Petzelbauer, P., Fredeking, T. M., & Ignatyev, G. (2003). Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunology & Medical Microbiology, 35(1), 33–42. https://doi.org/10.1111/j.1574-695x.2003.tb00646.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free